We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.88 | 1.19% | 1,094.99 | 1,094.18 | 1,100.00 | 1,100.08 | 1,079.0855 | 1,087.89 | 282,365 | 22:32:27 |
From Jul 2021 to Jul 2024
By Colin Kellaher
Regeneron Pharmaceuticals Inc. and Ultragenyx Pharmaceutical Inc. on Friday said they signed an international licensing agreement for Regeneron's cholesterol drug Evkeeza.
Under the agreement, Ultragenyx, a Novato, Calif., biopharmaceutical company, will develop, commercialize and distribute Evkeeza in countries outside the U.S., including in the European Economic Area, where Evkeeza was approved in June 2021.
Regeneron will receive a $30 million upfront payment and is eligible to receive up to $63 million in potential regulatory and sales milestones, the companies said.
Tarrytown, N.Y., biotechnology company Regeneron discovered Evkeeza and launched the drug in the U.S. last February for patients with homozygous familial hypercholesterolemia, an ultra-rare inherited form of high cholesterol. Regeneron said it will continue to solely sell Evkeeza in the U.S.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 07, 2022 07:34 ET (12:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
